News

Caretaker Medical Receives Inaugural Healthcare Tech Innovation Award and $200,000 Grant from Medical Society of D.C.

Caretaker Medical is honored to announce it has been awarded the Healthcare Technology Innovation Award, along with a $200,000 grant, from the Medical Society of the District of Columbia (MSDC) at the 5th annual Capital Healthcare Honors Gala. This prestigious award, presented on March 26, 2025, recognizes Caretaker Medical’s groundbreaking work in advancing wireless patient monitoring with its VitalStream platform.

The award, supported by a grant from The Institute for Technology in Healthcare, commemorates the legacy of Dr. Cesar A. C. Caceres, an esteemed medical professional dedicated to the application of technology to solve healthcare challenges. Dr. Caceres founded the Institute for Technology in Healthcare and was recognized for his pioneering work in computer-electrocardiographic interpretive systems.

“We are delighted to celebrate the memory and achievements of Dr. Caceres by presenting Caretaker Medical with this inaugural award,” said Matthew Lecuyer, MD, Healthy Physician Foundation board chair. “As technology improves patient care and physician wellbeing, this award connects the achievements of the past with the promise of the future.”

Caretaker Medical’s CEO, Jeff Pompeo, accepted the award on behalf of the company, expressing gratitude for the recognition of their commitment to improving patient care and physician health. “This award validates our dedication to providing patients and physicians with a much-needed wearable, continuous blood pressure monitoring solution,” said Pompeo.

VitalStream, Caretaker Medical’s US Food and Drug Administration-cleared wearable monitor, merges clinical accuracy with a wire-free, comfortable patient experience. The $200,000 grant will support the expansion of this innovative platform, which provides continuous blood pressure and hemodynamic monitoring.

The technology has demonstrated versatility in routine care and crisis response, proving invaluable in applications such as maternal health monitoring, perioperative recovery, and during the recent IV fluid shortages caused by Hurricane Helene. In these challenging times, VitalStream has helped healthcare providers maintain continuous blood pressure monitoring, ensuring patient safety and optimizing fluid management.

“VitalStream offers significant advantages for patients and providers in routine conditions, as well as unexpected and demanding circumstances,” said Johnny Mann, vice president of sales and marketing at Caretaker Medical. “Our technology can help ensure patient safety and optimize fluid management during some of the most challenging times.”

Caretaker Medical extends its deepest gratitude to the MSDC and The Institute for Technology in Healthcare for this honor and for their tireless efforts to advance healthcare in the Nation’s Capital Region and beyond.

Learn more here.

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and